A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

408

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Advanced Solid Tumors
Metastatic Solid Tumors

Interventions

DRUG: INCA33890
DRUG: bevacizumab
DRUG: FOLFIRI
DRUG: FOLFOX
DRUG: Cetuximab

Sponsor

Incyte Corporation